tetano
Editor, Senior Moderator
Genes Genomics
. 2023 Aug 7.
doi: 10.1007/s13258-023-01426-1. Online ahead of print. Proteome based analysis of circulating SARS-CoV-2 variants: approach to a universal vaccine candidate
Elijah Kolawole Oladipo[SUP] 1 2 [/SUP], Taiwo Ooreoluwa Ojo[SUP] 3 4 [/SUP], Seun Elijah Olufemi[SUP] 3 4 [/SUP], Boluwatife Ayobami Irewolede[SUP] 3 [/SUP], Daniel Adewole Adediran[SUP] 3 4 [/SUP], Asegunloluwa Grace Abiala[SUP] 3 5 [/SUP], Oluwaseun Samuel Hezekiah[SUP] 3 5 [/SUP], Akindele Felix Idowu[SUP] 3 4 [/SUP], Yinmi Gabriel Oladeji[SUP] 3 6 [/SUP], Mary Omotoyinbo Ikuomola[SUP] 3 5 [/SUP], Adenike Titilayo Olayinka[SUP] 3 7 [/SUP], Gideon Oluwamayowa Akanbi[SUP] 3 8 [/SUP], Usman Abiodun Idowu[SUP] 3 8 [/SUP], Odunola Abimbola Olubodun[SUP] 3 5 [/SUP], Folusho Daniel Odunlami[SUP] 3 5 [/SUP], James Akinwumi Ogunniran[SUP] 3 7 [/SUP], Omodamola Paulina Akinro[SUP] 3 8 [/SUP], Hadijat Motunrayo Adegoke[SUP] 3 9 [/SUP], Elizabeth Oluwatoyin Folakanmi[SUP] 3 5 [/SUP], Temitope Aishat Usman[SUP] 3 [/SUP], Elizabeth Folakemi Oladokun[SUP] 3 8 [/SUP], Glory Jesudara Oluwasanya[SUP] 3 [/SUP], Hezekiah Oluwajoba Awobiyi[SUP] 3 [/SUP], Jerry Ayobami Oluwasegun[SUP] 3 5 [/SUP], Samuel Adebowale Akintibubo[SUP] 3 8 [/SUP], Esther Moradeyo Jimah[SUP] 3 [/SUP]
Affiliations
The discovery of the first infectious variant in Wuhan, China, in December 2019, has posed concerns over global health due to the spread of COVID-19 and subsequent variants. While the majority of patients experience flu-like symptoms such as cold and fever, a small percentage, particularly those with compromised immune systems, progress from mild illness to fatality. COVID-19 is caused by a RNA virus known as severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Our approach involved utilizing immunoinformatic to identify vaccine candidates with multiple epitopes and ligand-binding regions in reported SARS-CoV-2 variants. Through analysis of the spike glycoprotein, we identified dominant epitopes for T-cells and B-cells, resulting in a vaccine construct containing two helper T-cell epitopes, six cytotoxic T-cell epitopes, and four linear B-cell epitopes. Prior to conjugation with adjuvants and linkers, all epitopes were evaluated for antigenicity, toxicity, and allergenicity. Additionally, we assessed the vaccine Toll-Like Receptors complex (2, 3, and 4). The vaccine construct demonstrated antigenicity, non-toxicity, and non-allergenicity, thereby enabling the host to generate antibodies with favorable physicochemical characteristics. Furthermore, the 3D structure of the B-cell construct exhibited a ProSA-web z-score plot with a value of -1.71, indicating the reliability of the designed structure. The Ramachandran plot analysis revealed that 99.6% of the amino acid residues in the vaccine subunit were located in the high favored observation region, further establishing its strong candidacy as a vaccination option.
Keywords: Covid-19; Immunoinformatic; Multi-epitope; SARS-Cov-2; Vaccine; Variant.
. 2023 Aug 7.
doi: 10.1007/s13258-023-01426-1. Online ahead of print. Proteome based analysis of circulating SARS-CoV-2 variants: approach to a universal vaccine candidate
Elijah Kolawole Oladipo[SUP] 1 2 [/SUP], Taiwo Ooreoluwa Ojo[SUP] 3 4 [/SUP], Seun Elijah Olufemi[SUP] 3 4 [/SUP], Boluwatife Ayobami Irewolede[SUP] 3 [/SUP], Daniel Adewole Adediran[SUP] 3 4 [/SUP], Asegunloluwa Grace Abiala[SUP] 3 5 [/SUP], Oluwaseun Samuel Hezekiah[SUP] 3 5 [/SUP], Akindele Felix Idowu[SUP] 3 4 [/SUP], Yinmi Gabriel Oladeji[SUP] 3 6 [/SUP], Mary Omotoyinbo Ikuomola[SUP] 3 5 [/SUP], Adenike Titilayo Olayinka[SUP] 3 7 [/SUP], Gideon Oluwamayowa Akanbi[SUP] 3 8 [/SUP], Usman Abiodun Idowu[SUP] 3 8 [/SUP], Odunola Abimbola Olubodun[SUP] 3 5 [/SUP], Folusho Daniel Odunlami[SUP] 3 5 [/SUP], James Akinwumi Ogunniran[SUP] 3 7 [/SUP], Omodamola Paulina Akinro[SUP] 3 8 [/SUP], Hadijat Motunrayo Adegoke[SUP] 3 9 [/SUP], Elizabeth Oluwatoyin Folakanmi[SUP] 3 5 [/SUP], Temitope Aishat Usman[SUP] 3 [/SUP], Elizabeth Folakemi Oladokun[SUP] 3 8 [/SUP], Glory Jesudara Oluwasanya[SUP] 3 [/SUP], Hezekiah Oluwajoba Awobiyi[SUP] 3 [/SUP], Jerry Ayobami Oluwasegun[SUP] 3 5 [/SUP], Samuel Adebowale Akintibubo[SUP] 3 8 [/SUP], Esther Moradeyo Jimah[SUP] 3 [/SUP]
Affiliations
- PMID: 37548884
- DOI: 10.1007/s13258-023-01426-1
The discovery of the first infectious variant in Wuhan, China, in December 2019, has posed concerns over global health due to the spread of COVID-19 and subsequent variants. While the majority of patients experience flu-like symptoms such as cold and fever, a small percentage, particularly those with compromised immune systems, progress from mild illness to fatality. COVID-19 is caused by a RNA virus known as severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Our approach involved utilizing immunoinformatic to identify vaccine candidates with multiple epitopes and ligand-binding regions in reported SARS-CoV-2 variants. Through analysis of the spike glycoprotein, we identified dominant epitopes for T-cells and B-cells, resulting in a vaccine construct containing two helper T-cell epitopes, six cytotoxic T-cell epitopes, and four linear B-cell epitopes. Prior to conjugation with adjuvants and linkers, all epitopes were evaluated for antigenicity, toxicity, and allergenicity. Additionally, we assessed the vaccine Toll-Like Receptors complex (2, 3, and 4). The vaccine construct demonstrated antigenicity, non-toxicity, and non-allergenicity, thereby enabling the host to generate antibodies with favorable physicochemical characteristics. Furthermore, the 3D structure of the B-cell construct exhibited a ProSA-web z-score plot with a value of -1.71, indicating the reliability of the designed structure. The Ramachandran plot analysis revealed that 99.6% of the amino acid residues in the vaccine subunit were located in the high favored observation region, further establishing its strong candidacy as a vaccination option.
Keywords: Covid-19; Immunoinformatic; Multi-epitope; SARS-Cov-2; Vaccine; Variant.